Full-Time

Senior Director

Clinical Operations

Posted on 10/7/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$260k - $275k/yr

Princeton, NJ, USA

Hybrid

Hybrid work model with an expected on-site presence of two days per week.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in Life Sciences, Nursing, Pharmacy, or a closely discipline is required.
  • Advanced degree such as Master’s, PharmD, PhD, or MBA is strongly preferred, particularly with a focus in clinical research, healthcare, or business administration.
  • Minimum of 12 years of progressive experience in clinical operations or clinical study management within the pharmaceutical, biotechnology, or CRO industry, including extensive senior leadership responsibility for global teams and full clinical development lifecycles.
  • Proven success in leading complex, global Phase I–IV clinical programs in matrixed, cross-regional environments; oncology and/or rare disease experience strongly preferred.
  • Demonstrated expertise in early-phase development, with hands-on experience managing trials across diverse regulatory landscapes (e.g., FDA, EMA, PMDA).
  • Extensive experience in CRO and vendor oversight, including performance management, quality control, and hybrid operating models and vendor selection to ensure high-quality and timely trial execution.
  • Strong track record of regulatory compliance and inspection readiness, including audit preparation, response, and CAPA execution.
  • Proven ability to lead, develop, and engage cross-functional, multi-regional teams, effectively managing across time zones and cultures.
  • Demonstrated capability in driving operational excellence, including process optimization, metrics-based performance management, and adoption of innovative technologies (e.g., AI, digital platforms).
  • Deep knowledge of global regulatory frameworks and clinical development standards, including FDA, EMA, PMDA regulations, and ICH-GCP guidelines.
  • Proven expertise in process optimization, risk mitigation, and quality management systems to drive operational excellence and compliance.
  • Proficient in clinical trial documentation and operational systems, including Clinical Trial Management Systems (CTMS), electronic Trial Master File (eTMF), and project management tools such as Planisware or similar platforms.
  • Skilled in budget planning, financial oversight, and contract negotiations, collaborating closely with finance and legal teams to ensure cost-effective clinical program delivery.
  • Strong command of data analytics and performance metrics, leveraging dashboards and KPIs to monitor study progress and inform strategic decisions.
  • Experience with digital R&D intelligence platforms (e.g., Citeline, Trialtrove) and a strong understanding of emerging clinical technologies, including AI-driven tools, eConsent, remote monitoring, and decentralized trial solutions.
  • Excellent written, verbal, and listening communication skills; articulate and effective communicator and presenter, including global audience.
  • Proficiency in Microsoft Office Suite (Excel, Word, Outlook, etc.).
Responsibilities
  • Lead Kyowa Kirin’s Clinical Operations across North America and Europe, serving as the regional head responsible for the successful planning, execution, and delivery of all clinical trial activities in these territories.
  • Provide strategic and operational leadership to regional clinical operations teams, ensuring alignment with global development priorities and company objectives.
  • Act as key leader within the Clinical Operations organization, representing NA/EU regions on cross-regional leadership teams, governance bodies, and strategic initiatives.
  • Drive cross-functional collaboration with global functions including Development, Quality Assurance, Regulatory, Finance, Clinical Supplies, Legal, and external partners, operating effectively within a matrixed structure.
  • Mentor, coach, and develop regional clinical leaders and staff, cultivating a high-performing, inclusive, and culturally aware organization.
  • Promote transparent communication and strong collaboration across regions, time zones, and cultural boundaries to ensure operational alignment and team cohesion.
  • Lead the planning, execution, and closeout of all NA/EU clinical trials, ensuring delivery on time, within budget, and in full compliance with global regulatory and quality standards (ICH-GCP, FDA, EMA, PMDA).
  • Oversee integrated trial execution models, managing a hybrid approach that includes both in-house operations and external CRO/vendor partnerships to ensure consistent quality and performance.
  • Collaborate with CROs and functional leads on site feasibility and capability assessments, driving optimal site selection, accelerated activation timelines, and strong patient recruitment and retention strategies.
  • Champion and implement scalable, technology-enabled trial capabilities, integrating AI, digital health tools, and patient-centric innovations to enhance trial efficiency and experience.
  • Lead and contribute to global process improvement initiatives, helping to refine governance structures, operational models, and best practices across the Clinical Operations organization.
  • Ensure all clinical trials are inspection-ready at all times, maintaining full compliance with ICH-GCP, local regulatory requirements, and internal quality standards.
  • Oversee end-to-end trial quality management, including proactive risk identification, audit preparedness, inspection response coordination, and timely completion of CAPAs.
  • Maintain and enhance SOPs, training programs, and compliance frameworks to support high standards of quality and consistency across clinical operations teams.
  • Lead global operational excellence initiatives focused on process harmonization, risk mitigation, and implementation of performance metrics to drive continuous improvement.
  • Establish and nurture strong partnerships with key internal and external stakeholders—including senior leadership, investigators, and KOLs—to align quality objectives and promote accountability.
Desired Qualifications
  • Oncology and/or rare disease experience strongly preferred.

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE